Inactive Instrument

News Mylan Inc Nasdaq

Equities

US6285301072

End-of-day quote Nasdaq Other stock markets
- ^USD	-

03:24pm	Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says	MT
02:04pm	UK Regulator to Consider Undertakings for Theramex-Viatris Deal	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says	09:24am	MT
UK Regulator to Consider Undertakings for Theramex-Viatris Deal	08:04am	MT
Viatris to Report First Quarter 2024 Financial Results on May 9, 2024	Apr. 16	PR
Viatris Launches New Generic Treatment Option for Multiple Sclerosis in Canada	Apr. 15	MT
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	Apr. 15	AQ
Viatris Appoints Corinne Le Goff as Chief Commercial Officer	Apr. 15	PR
Viatris Inc. Appoints Corinne Le Goff as Chief Commercial Officer	Apr. 15	CI
Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada	Apr. 15	AQ
Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada	Apr. 15	CI
Atomo Diagnostics Wins AU$570,000 HIV Self-Tests Order	Apr. 14	MT
Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc	Apr. 11	CI
UK's Theramex sees no impact to HRT products supply after CMA probe	Apr. 05	RE
Pharma deal could reduce choice and lead to higher prices for HRT treatments	Apr. 04	AQ
UK Regulator Finds Competition Concerns in Theramex-Viatris Merger Deal	Apr. 04	MT
UK watchdog says Theramex-Viatris deal raises competition concerns	Apr. 04	RE
Viatris Announces the Launch of RYZUMVl 0.75% in the United States	Apr. 02	AQ
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	Apr. 01	MT
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	Apr. 01	MT
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent	Apr. 01	RE
Viatris Launches of Ryzumvi Eye Drops to Reverse Dilation in US	Apr. 01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Mylan Inc Nasdaq

Equities

US6285301072

Summary

Filters